The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells-Reference-Cited by-同舟云学术

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

Published:2019-07-03 Issue:499 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Mestermann Katrin¹^ORCID,Giavridis Theodoros²,Weber Justus¹,Rydzek Julian¹,Frenz Silke¹^ORCID,Nerreter Thomas¹^ORCID,Mades Andreas¹^ORCID,Sadelain Michel²^ORCID,Einsele Hermann¹,Hudecek Michael¹^ORCID

Affiliation:

1. Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, 97080 Würzburg, Germany.

2. Center for Cell Engineering and Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Abstract

Dasatinib is a pharmacologic switch for CARs that enables physicians to control CAR T cell function in real time.

Funder

Alexander S. Onassis Public Benefit Foundation

Deutsche Krebshilfe

Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg

MSK Cancer Center

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference26 articles.

1. Chimeric Antigen Receptor Therapy

2. Therapeutic T cell engineering

3. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

4. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

5. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

Cited by 365 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation of CAR transgene expression to design semiautonomous CAR-T;Molecular Therapy: Oncology;2024-09

2. Synthesis, molecular modeling simulations and anticancer activity of some new Imidazo[2,1-b]thiazole analogues as EGFR/HER2 and DHFR inhibitors;Bioorganic Chemistry;2024-09

3. Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies;Blood Reviews;2024-09

4. T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells;Blood Advances;2024-08-30

5. Frontiers and challenges of immune cell therapy research in solid tumors;Chinese Science Bulletin;2024-08-20